Chemotherapy: Impact on Anti- Müllerian Hormone Levels in Breast Carcinoma | Zendy

Jyoti Bala | Zendy; Shashi Seth | Zendy; Rakesh Dhankhar | Zendy; Veena Singh Ghalaut | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chemotherapy: Impact on Anti- Müllerian Hormone Levels in Breast Carcinoma

Author(s) -

Jyoti Bala,

Shashi Seth,

Rakesh Dhankhar,

Veena Singh Ghalaut

Publication year - 2016

Publication title -

journal of clinical and diagnostic research

Language(s) - English

Resource type - Journals

eISSN - 2249-782X

pISSN - 0973-709X

DOI - 10.7860/jcdr/2016/15933.7328

Subject(s) - anti müllerian hormone , medicine , ovarian reserve , breast cancer , chemotherapy , breast carcinoma , oncology , hormone , gynecology , cancer , biology , infertility , pregnancy , genetics

Anti-Mullerian Hormone (AMH) is a glycoprotein of the transforming growth factor-β (TGF-β) family that seems to reflect the continuous non-cyclical growth of small follicles and can be considered an indirect index of the size of the resting primordial follicle pool. Accordingly, AMH represents a marker of Ovarian Reserve (OR) and is particularly useful in demonstrating ovarian tissue damage induced by chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research